Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Toxicological Effects
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics

Brand Names


Austria: Condylox; Belgium: Wartec; Bulgaria: Condylin; Czech Republic: Wartec; Denmark: Condyline, Wartec; Estonia: Wartec; Finland: Condyline, Wartec; France: Condyline; Germany: Condylox, Wartec; Greece: Podofilox, Wartec; Ireland: Condyline, Warticon; Italy: Condyline; Lithuania: Wartec; Netherlands: Condyline, Wartec; Poland: Condyline, Wartec; Romania: Condyline, Wartec; Slovakia: Wartec; Spain: Wartec; Sweden: Wartec; UK: Warticon.

North America

Canada: Condyline, Wartec; USA: Condylox, Podofilox.

Latin America

Argentina: Podoxín; Brazil: Wartec; Mexico: Wartec.

Drug combinations


Podofilox: C~22~H~22~O~8~. Mw: 414.41. (1) Furo[3′,4′:6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-, [5R-(5α,5aβ,8aα,9α)]-; (2) Podophyllotoxin; (3)(5R,5aR,8aR,9R)-5,8,8a,9-Tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)furo[3′,4′:6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one. CAS-518-28-5 (1989).

Pharmacologic Category

Skin and Mucous Membrane Agents, Miscellaneous; Keratolytic Agent. (ATC-Code: D06BB04).

Mechanism of action

The effect on Human papillomavirus (HPV) warts may be related to interference with microtubular function of keratinocytes contained in warts and local vascular structures and may also be related to local immunomodulating effects. May have anti-inflammatory activity related to decrease in tumor necrosis factor receptors.

Therapeutic use

Treatment of external genital warts.

Pregnancy and lactiation implications

Unknown whether topically applied podofilox distributed into human milk. Use with caution during pregnancy or lactation.

Unlabeled use


Known hypersensitivity or intolerance to podofilox or any ingredient in the formulation.

Warnings and precautions

HIV-infected individuals may not respond as well and may have more frequent recurrences of genital HPV warts after treatment compared with immunocompetent individuals. Women with genital HPV warts should be advised to undergo regular Papanicolaou tests as recommended for women without genital HPV warts.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart